Clinical benefit from anti-PD-1/PD-L1 therapy is associated with high tumor mutational load, high levels of pre-treatment tumor-infiltrating T cells, and high expression of pre-treatment PD-L1 on tumor cells and tumor-infiltrating immune cells (14). The gene discussed is CD274; the disease is neoplasm.